Replies to post #806218 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The Advisor Committee Recommendation to FDA is non binding. If the the committee has concerns about the drug being review still the FDA has to issue the letter of concerns and need to be addressed by the sponsor within 6 days.

Where do you guys come up with this?

The FDA issues letters of concern about drugs that are being marketed, not about the status of a BLA/NDA. Further, the FDA ADCOM is public, there is no need to inform the company what the ADCOM said.

As far NWBO and a CHM letter, we have no idea if such was issued already. The assertion NWBO must disclose is comical when NWBO has failed in the past to disclose negative material information and also as NWBO said they would update on a final action which will likely never happen).